Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVGRNASDAQ:IINNNASDAQ:LYRANASDAQ:QNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVGRAvinger$0.47$0.47$0.36▼$2.43$1.57M1.091.16 million shsN/AIINNInspira Technologies Oxy B.H.N.$0.43-2.7%$0.59$0.40▼$2.39$5.42M2.15426,114 shs294,359 shsLYRALyra Therapeutics$4.39$0.19$3.81▼$17.20$290.91M0.0438,056 shs134,345 shsQNRXQuoin Pharmaceuticals$9.37-5.0%$7.35$5.01▼$54.95$5.51M1.39136,181 shs15,985 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVGRAvinger0.00%0.00%0.00%0.00%-79.12%IINNInspira Technologies Oxy B.H.N.-2.70%-13.56%-30.49%-48.24%-78.52%LYRALyra Therapeutics+4,900.00%+4,570.21%+4,312.06%+2,051.96%+1,216.34%QNRXQuoin Pharmaceuticals-4.97%+10.63%+41.97%-24.63%-62.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVGRAvingerN/AN/AN/AN/AN/AN/AN/AN/AIINNInspira Technologies Oxy B.H.N.0.8517 of 5 stars0.03.00.00.02.51.70.6LYRALyra Therapeutics1.1766 of 5 stars1.24.00.00.03.21.70.6QNRXQuoin Pharmaceuticals0.3759 of 5 stars0.03.00.00.01.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVGRAvinger 0.00N/AN/AN/AIINNInspira Technologies Oxy B.H.N. 0.00N/AN/AN/ALYRALyra Therapeutics 2.33Hold$2.00-54.44% DownsideQNRXQuoin Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AVGR, LYRA, IINN, and QNRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/14/2025LYRALyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVGRAvinger$7.26M0.22N/AN/A($4.53) per share-0.10IINNInspira Technologies Oxy B.H.N.N/AN/AN/AN/A$0.45 per shareN/ALYRALyra Therapeutics$1.19M245.50N/AN/A$1.56 per share2.81QNRXQuoin PharmaceuticalsN/AN/AN/AN/A$5.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVGRAvinger-$18.32M-$11.06N/AN/AN/A-261.06%-5,527.11%-123.25%8/6/2025 (Estimated)IINNInspira Technologies Oxy B.H.N.-$11.29MN/A0.00∞N/AN/AN/AN/A6/9/2025 (Estimated)LYRALyra Therapeutics-$62.68M-$1.21N/AN/AN/A-6,635.76%-125.07%-59.74%8/12/2025 (Estimated)QNRXQuoin Pharmaceuticals-$8.69M-$48.81N/AN/AN/AN/A-125.60%-64.77%8/14/2025 (Estimated)Latest AVGR, LYRA, IINN, and QNRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025QNRXQuoin Pharmaceuticals-$3.85-$6.50-$2.65-$6.50N/AN/A5/6/2025Q1 2025LYRALyra Therapeutics-$0.15-$0.12+$0.03-$0.13$0.16 million$0.18 million3/13/2025Q4 2024LYRALyra Therapeutics-$0.12-$0.16-$0.04-$0.16$0.21 million$0.21 million3/13/2025Q4 2024QNRXQuoin Pharmaceuticals-$17.50-$12.25+$5.25-$0.35N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVGRAvingerN/AN/AN/AN/AN/AIINNInspira Technologies Oxy B.H.N.N/AN/AN/AN/AN/ALYRALyra TherapeuticsN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVGRAvingerN/A1.210.81IINNInspira Technologies Oxy B.H.N.0.092.232.13LYRALyra TherapeuticsN/A3.643.64QNRXQuoin PharmaceuticalsN/A3.023.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVGRAvinger18.30%IINNInspira Technologies Oxy B.H.N.12.72%LYRALyra Therapeutics95.62%QNRXQuoin Pharmaceuticals8.63%Insider OwnershipCompanyInsider OwnershipAVGRAvinger42.80%IINNInspira Technologies Oxy B.H.N.29.40%LYRALyra Therapeutics3.25%QNRXQuoin Pharmaceuticals3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVGRAvinger703.31 million1.89 millionNot OptionableIINNInspira Technologies Oxy B.H.N.2012.62 million8.91 millionNot OptionableLYRALyra Therapeutics5066.27 million62.39 millionOptionableQNRXQuoin Pharmaceuticals4588,0004.86 millionNot OptionableAVGR, LYRA, IINN, and QNRX HeadlinesRecent News About These CompaniesQuoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical StudyMay 22, 2025 | manilatimes.netQuoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton SyndromeMay 20, 2025 | globenewswire.comQuoin reports progress in pediatric skin disorder studyMay 15, 2025 | investing.comQuoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome StudyMay 14, 2025 | globenewswire.comQuoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial ResultsMay 14, 2025 | manilatimes.netA Peek at Quoin Pharmaceuticals's Future EarningsMay 12, 2025 | benzinga.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleMay 1, 2025 | finanznachrichten.deQuoin Pharmaceuticals regains Nasdaq compliance with bid priceMay 1, 2025 | investing.comQuoin Pharmaceuticals regains Nasdaq complianceApril 30, 2025 | msn.comQuoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleApril 30, 2025 | globenewswire.comWhy Quoin Pharmaceuticals, Ltd.’s (QNRX) Stock Is Down 13.50%April 10, 2025 | aaii.comQuoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaignApril 10, 2025 | globenewswire.comQuoin Pharmaceuticals Ltd – ADR trading halted, news pendingApril 9, 2025 | markets.businessinsider.comQuoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirementsApril 6, 2025 | uk.investing.comQuoin announces additional data from Pediatric Netherton Syndrome studyApril 3, 2025 | markets.businessinsider.comQuoin Reports Clinically Meaningful Whole Body Response to QRX003 in Pediatric Netherton Syndrome; Second Patient Cleared for DosingApril 2, 2025 | reuters.comQuoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric PatientApril 2, 2025 | globenewswire.comQuoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin DiseasesMarch 25, 2025 | globenewswire.comQNRX: With Clinical Activities Expanding, QNRX Expects Cash Runway Into 2Q26March 18, 2025 | msn.comQuoin Pharmaceuticals reports Q4 EPS (35c) vs ($2.08) last yearMarch 13, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVGR, LYRA, IINN, and QNRX Company DescriptionsAvinger NASDAQ:AVGR$0.47 0.00 (0.00%) As of 05/27/2025Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.Inspira Technologies Oxy B.H.N. NASDAQ:IINN$0.43 -0.01 (-2.70%) Closing price 05/28/2025 03:58 PM EasternExtended Trading$0.43 +0.00 (+1.02%) As of 05/28/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel.Lyra Therapeutics NASDAQ:LYRA$4.39 0.00 (0.00%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$4.42 +0.04 (+0.80%) As of 05/28/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Quoin Pharmaceuticals NASDAQ:QNRX$9.37 -0.49 (-4.97%) Closing price 05/28/2025 03:59 PM EasternExtended Trading$9.29 -0.08 (-0.90%) As of 05/28/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
